Helyx Industries SpA

Helyx Industries has a market price of 0.622 EUR and a market cap of 16,202,843.11 EUR, with a price-to-book ratio of 0.81 and a price-to-tangible-book ratio of 0.81. The company's enterprise value to EBITDA is -3.63, and its enterprise value to revenue is 8.26. The return on equity is -0.2195, and the return on assets is -0.184, indicating significant underperformance relative to industry norms. The company's debt-to-equity ratio is 0.05, and its current ratio is 2.76, suggesting a relatively strong liquidity position. However, the operating cash flow is -1,751,350 EUR, and the free cash flow is -1,575,070 EUR, indicating ongoing cash flow challenges. The capital expenditure is -144,930 EUR, reflecting minimal investment in new assets. Helyx Industries' revenue is 1,932,180 EUR, with a gross profit of -27,600 EUR and an operating income of -4,396,430 EUR. The net income is -4,415,920 EUR, highlighting the company's current unprofitability. The company's total assets are 23,994,290 EUR, with total liabilities of 3,878,140 EUR and total equity of 20,116,150 EUR. The company's long-term debt is 1,025,760 EUR, and its cash and equivalents are 1,261,730 EUR. The company's liquidity risk is assessed as low, and the dilution risk is also low, with no immediate filing-based liquidity or dilution flags detected. Helyx Industries' revenue is concentrated in the healthcare diagnostics segment, with no disclosed geographic diversification. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's recent events include the development of diagnostic platforms such as Sagitta, NanoHybrid, and Aptavir, which are used for various diagnostic applications.